This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Redcare Phamacy Unsp/Adr
Q42023
3/5/2024
Operator
Conference Operator
At this time, it's my pleasure to hand over to Olaf Heinrich, CEO. Please go ahead, sir.
Olaf Heinrich
CEO
Well, thank you very much and also very well welcome from my side. We are happy to have you today with us and to present the 2023 RETCAN numbers. 2023 has been a great year for RETCAN. Let's have a quick look into the agenda. First of all, we would like to look into some highlights of 2023. then looking into the business performance of 2023, and afterwards, strategic update and outlook 2024, and then financial outlook and guidance of 2024. Can you please go to the next slide? So I think we need to start with the guidance. I mean, you know, it has already been a revised guidance, and we fully achieved the guidance across all elements, with record sales and major margin improvement.
Patrick Holstein
Analyst, Apotheke
So we're really happy about that.
You're reading a preview of the SAEYY Q4 2023 earnings call.
Free account.
Disclaimer